Next-generation AI cardiac imaging platform launches with new, FDA-approved modules
Click Here to Manage Email Alerts
Arterys announced it has added several new elements to its artificial intelligence-enhanced cardiac MRI platform and an additional FDA clearance for two quantification modules.
According to a company press release, Arterys’ platform (Cardio AI) is a cloud-based post-processing solution that utilizes AI and deep learning to provide automated, repeatable analysis of cardiac MRI images.
The newly added modules include:
- a deep learning myocardial velocity and strain model that eliminates the need for contour editing to obtain reliable strain results, for research use only (Strain + AIPowered by 4D Flow);
- a module that quantify volumes for left and right atria in cardiac MRI images (Atrial Volumes); and
- automatic wall thickness measurements (Wall Thickness).
The company also announced the FDA clearance of its T1 plus AI, and T2 quantification modules.
According to the release, these modules provide a dedicated workflow for T1 and extracellular volume, and T2 quantification, including multiple and global regions of interest, and a graphical display of curves that provides users with calculations for tissue characterization.
“Cardio AI has been an invaluable tool in our practice to allow us faster processing of complex cardiac MR examinations with automated contouring not only for function, but also tissue characterization, saving us minutes of processing time on every single exam,” Melany B. Atkins, MD, division chief of body and cardiovascular imaging at Inova Fairfax Hospital in Falls Church, Virginia, said in the release. “Rapid processing of 4D Flow affords us the ability to evaluate complex congenital heart disease nearly [in] real time.”
Collapse
Click Here to Manage Email Alerts